 Home > Active Ingredient News > Digestive System Information > AP&T: The loss of response to anti-TNFα drugs in patients with inflammatory bowel disease depends on the duration of treatment

AP&T: The loss of response to anti-TNFα drugs in patients with inflammatory bowel disease depends on the duration of treatment

 Last Update: 2021-11-11
 Source: Internet
 Author: User

Tags

a d1

platelet factor 4

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In 1992, the first patient with severe Crohn’s disease (CD) received anti-tumor necrosis factor (TNF) antibody treatment at the Medical Center (AMC) in Amsterdam, the Netherlands.

This is a multicenter, retrospective cohort study of patients with ulcerative colitis (UC) or Crohn's disease (CD) who received anti-TNFα therapy for at least 4 months between 2011 and 2019

Ulcerative colitis

A total of 708 patients with inflammatory bowel disease were included in the study, and all patients received a total of 844 anti-TNFα treatments

immunity

With the passage of time, the incidence of anti-TNFα discontinuation, anti-TNFα discontinuation due to the occurrence of side effects, and dose increase significantly decreased

Johannes PD et al.

Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Wholesale Magnesium Oxide Raw Materials CAS 1309-48-4 99% Powder Evergreen EGC-Magnesium Oxide Powder

CAS No.: 1309-48-4

Food Grade

$70-76/KG FOB

Ranitidine HCL CAS 66357-59-3

CAS No.: 66357-59-3

Pharmacy Grade

$88-98/KG FOB

Antifoam SAG-7133

CAS No.: 8050-81-5

Industrial Grade

$9999/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.